206
M. Irfan et al.
127. Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA (2002) RNA
aptamers as reversible antagonists of coagulation factor IXa. Nature 419(6902):90–94
128. Nimjee SM, Povsic TJ, Sullenger BA, Becker RC (2016) Translation and clinical development
of antithrombotic aptamers. Nucl acid Ther 26(3):147–155
129. Becker RC, Rusconi C, Sullenger B (2005) Nucleic acid aptamers in therapeutic anticoagulation. Thromb Haemost 93(06):1014–1020
130. Bompiani K, Monroe D, Church F, Sullenger B (2012) A high affinity, antidote-controllable
prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin
activity. J Thromb Haemost 10(5):870–880
131. Öztürk-Atar K, Ero˘ glu H, Çalı¸ s S (2018) Novel advances in targeted drug delivery. J Drug
Target 26(8):633–642
132. Yoon S, Rossi JJ, Aptamers in molecular imaging: from principles to biological applications
133. Chen Z, Krishnamachary B, Pachecho-Torres J, Penet MF, Bhujwalla ZM (2020) Theranostic
small interfering RNA nanoparticles in cancer precision nanomedicine. Wiley Interdiscip Rev
Nanomedicine Nanobiotechnology 12(2):e1595
134. Fu Z, Xiang J (2020) Aptamers, the nucleic acid antibodies, in Cancer Therapy. Int J Mol Sci
21(8):2793
135. Yang W, Gadgil P, Krishnamurthy VR, Landis M, Mallick P, Patel D, Patel PJ, Reid DL,
Sanchez-Felix M (2020) The evolving druggability and developability space: chemically
modified new modalities and emerging small molecules. AAPS J 22(2):21
M. Irfan et al.
127. Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA (2002) RNA
aptamers as reversible antagonists of coagulation factor IXa. Nature 419(6902):90–94
128. Nimjee SM, Povsic TJ, Sullenger BA, Becker RC (2016) Translation and clinical development
of antithrombotic aptamers. Nucl acid Ther 26(3):147–155
129. Becker RC, Rusconi C, Sullenger B (2005) Nucleic acid aptamers in therapeutic anticoagulation. Thromb Haemost 93(06):1014–1020
130. Bompiani K, Monroe D, Church F, Sullenger B (2012) A high affinity, antidote-controllable
prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin
activity. J Thromb Haemost 10(5):870–880
131. Öztürk-Atar K, Ero˘ glu H, Çalı¸ s S (2018) Novel advances in targeted drug delivery. J Drug
Target 26(8):633–642
132. Yoon S, Rossi JJ, Aptamers in molecular imaging: from principles to biological applications
133. Chen Z, Krishnamachary B, Pachecho-Torres J, Penet MF, Bhujwalla ZM (2020) Theranostic
small interfering RNA nanoparticles in cancer precision nanomedicine. Wiley Interdiscip Rev
Nanomedicine Nanobiotechnology 12(2):e1595
134. Fu Z, Xiang J (2020) Aptamers, the nucleic acid antibodies, in Cancer Therapy. Int J Mol Sci
21(8):2793
135. Yang W, Gadgil P, Krishnamurthy VR, Landis M, Mallick P, Patel D, Patel PJ, Reid DL,
Sanchez-Felix M (2020) The evolving druggability and developability space: chemically
modified new modalities and emerging small molecules. AAPS J 22(2):21